Who 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors

Haznedaroğlu, İbrahim C.; Kuzu, Işınsu; İlhan, Osman

doi:10.4274/tjh.galenos.2019.2019.0241

Cited by 13 publications

(16 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 Frontline use of second generation TKIs, such as nilotinib or dasatinib, is often selected in patients with higher percentages of blasts, basophils, and eosinophils as well as those with thrombocytosis, bone marrow fibrosis, and massive splenomegaly. 12 Our patient had pronounced leukocytosis, myelofibrosis, and multiple cutaneous nodules. Theoretically, the optimal therapy would be the second generation TKIs.…”

mentioning

confidence: 63%

Mass‐forming neoplastic extramedullary hematopoiesis mimics myeloid sarcoma in a patient with chronic phase chronic myeloid leukemia

Singhi

Apostolidou

et al. 2020

Int J Lab Hematology

View full text Add to dashboard Cite

mentioning

confidence: 63%

Mass‐forming neoplastic extramedullary hematopoiesis mimics myeloid sarcoma in a patient with chronic phase chronic myeloid leukemia

Singhi

Apostolidou

et al. 2020

Int J Lab Hematology

View full text Add to dashboard Cite

“…We used total sampling method to recruit the patients (a total of 26 participants in each study group were needed as the minimum sample size according to the estimation that the prevalence of CML was 10-12 per 100,000 inhabitants with a 5% margin of error and 95% confidence level) [15]. The inclusion criteria were: (1) All CML patients treated in our hospital during the study period (the diagnosis criteria were adapted from previous study) [16], (2) CML patients treated with standard IM 400 mg/day for at least 6 months [17], (3) aged more than 18 years old, and (4) providing the written informed consent to participate in the study. The exclusion criteria were (1) patients treated with other TKI medications, (2) patients with drugs consumption that may reduce the efficacy of IM such as prazosin, proton pump inhibitors, and erythromycin, and (3) patients suffering from diseases that may associate with increased levels of FoxO3a such as chronic obstructive pulmonary disease (COPD), vitiligo, prostate cancer, thyroid, breast, and gynecological cancer.…”

Section: Study Design and Patientsmentioning

confidence: 99%

The Levels of FoxO3a Predict the Failure of Imatinib Mesylate Therapy among Chronic Myeloid Leukemia Patients

Wardhani

Susanti

Rahayu

et al. 2021

Open Access Maced J Med Sci

View full text Add to dashboard Cite

INTRODUCTION: Forkhead Transcription Factor 3a (FoxO3a) has been proposed to have a high efficacy to predict the failure of imatinib mesylate (IM) therapy among Chronic Myeloid Leukemia (CML) patients. However, the limited evidence had made this marker remained controversy. OBJECTIVES: We aimed to investigate the correlation between the levels of FoxO3a and the risk of treatment failure of IM therapy in CML patients. METHODS: A prospective cohort study was carried out between February 2019 and February 2020 in Saiful Anwar Hospital, Malang, Indonesia. All CML patients treated with IM on our hospital during the study period were included. The levels of FoxO3a was determined using the Enzyme-linked immunosorbent assay (ELISA) using Cusabio Biotech Kit (Cusabio Biotech Co., New York, USA). The treatment response was assessed using the European Leukemia criteria. The correlation and effect estimate between the levels of FoxO3a and treatment response of CML patients was assessed using multiple logistic regression. RESULTS: 53 CML patients receiving IM in our hospital were included, consisting of 29 patients with good response and 24 patients with non-response. Our study found that CML patients with lower levels of FoxO3a was associated with increased risk to develop treatment failure when treated with IM. Moreover, we also found that higher risk of treatment failure of IM therapy was also found in patients with increased levels of thrombocytes, basophils, and leukocytes, and lower levels of hemoglobin. CONCLUSION: We reveal that FoxO3a is the prominent marker to predict the treatment response of CML patients treated with IM.

show abstract

“…CML may be diagnosed in any of the three phases. Chronic phase which is the initial phase of CML characterized by increased neutrophils with various early-stage granulocytic precursors; accelerated phase which is characterized by 10–19% blasts in the bone marrow or peripheral blood, genomic evolution, persistent or increasing abnormal blood counts despite TKI treatment, (leukocytosis (> 10 × 109/L), thrombocytosis (> 1000 × 109/L), or thrombocytopenia (< 100 × 109/L) unrelated to therapy, 20% or more basophils and splenomegaly; blastic phase which is characterized by more than 20% blasts in blood or bone marrow or extramedullary blastic infiltration, genomic evolution, splenomegaly [ 7 ] Myelosuppression may develop during treatment of CML with imatinib, a TKI, especially in the setting of advanced disease [ 8 ]. In first line therapy, imatinib 400 mg daily induces more neutropenia than nilotinib and bosutinib and slightly less than dasatinib.…”

Section: Introductionmentioning

confidence: 99%

Baseline blood count levels increase odds of cytopenia among CML patients in Kenya: a case control study

et al. 2022

View full text Add to dashboard Cite

Background Imatinib is the gold standard for the treatment of all phases of Philadelphia positive Chronic Myeloid Leukemia (CML). During treatment, patients may develop cytopenia. We aimed to study the baseline characteristics and factors associated with cytopenia at a Nairobi Hospital. Methods This was a retrospective case-control study of patients aged ≥18 years on follow-up at the Glivec International Patient Access Program (GIPAP) clinic from 2007 to 2015. The cases consisted of CML patients on imatinib who developed cytopenia. The controls were CML patients on imatinib who did not develop cytopenia. Baseline socio – demographic, clinical, hematologic, and molecular data were retrieved from patients’ files. Chi square or fishers’ exact tests were used to analyze for differences between cytopenia and no cytopenia. Binary logistic regressions were employed to identify relationships. Univariate and multivariate analyses were done to identify independent predictors of cytopenia. Odds ratios (OR) were presented including the 95% confidence intervals and respective p values. Results A total of 201 patients were studied consisting of ninety-four (94) patients with cytopenia and 107 with no cytopenia. Among the entire population, males were 52, and 42% were aged 36–50 years. Sex, age, marital status, occupation and education level were similar between the cytopenia and no cytopenia groups. Among the 201 patients, 70% had symptoms for > 12 months before diagnosis, 78.6% had B symptoms at baseline, 80% had a moderate splenomegaly at baseline. Among patients with cytopenia, 40 and 37.4% developed cytopenia within 3 months and 3–6 months respectively after imatinib initiation. Baseline neutrophilia, neutropenia, anaemia, thrombocytosis, thrombocytopenia was found in 68, 11, 11, 23.5 and 11% respectively. Baseline hemoglobin, neutrophil and platelet level were significantly different between the cytopenia and the no cytopenia group. On univariable analysis, baseline anemia with hb < 7.9 g/dL (p = 0.002), neutropenia (p = 0.001), neutrophilia > 100,000/mm3 (p = 0.002) and thrombocytopenia (p = 0.001) increased the odds of developing cytopenia. On multivariable analysis, baseline anaemia (p value < 0.002), neutropenia (p value < 0.001), thrombocytopenia (p value, < 0.001) and thrombocytosis (p value, 0.033) increased the odds of developing cytopenia. Conclusion Odds of cytopenia were higher in presence of baseline cytopenia and thrombocytosis. Clinicians should have a high index of suspicion for these patients.

show abstract

Who 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors

Cited by 13 publications

References 30 publications

Mass‐forming neoplastic extramedullary hematopoiesis mimics myeloid sarcoma in a patient with chronic phase chronic myeloid leukemia

Mass‐forming neoplastic extramedullary hematopoiesis mimics myeloid sarcoma in a patient with chronic phase chronic myeloid leukemia

The Levels of FoxO3a Predict the Failure of Imatinib Mesylate Therapy among Chronic Myeloid Leukemia Patients

Baseline blood count levels increase odds of cytopenia among CML patients in Kenya: a case control study

Contact Info

Product

Resources

About